Is the bioavailability of the oral tablet and intravenous formulation of linezolid the same?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, the bioavailability of oral tablet and intravenous linezolid is essentially identical at approximately 100%.

Linezolid can be given orally or intravenously without dose adjustment because the absolute bioavailability of the oral formulation is approximately 100% 1, 2. This exceptional bioavailability makes linezolid unique among antibiotics and allows seamless conversion between routes of administration.

Pharmacokinetic Evidence

The FDA drug label explicitly states that linezolid is "extensively absorbed after oral dosing" with "absolute bioavailability approximately 100%" 1, 2. This means:

  • Maximum plasma concentrations (Cmax) are reached 1-2 hours after oral dosing
  • Area under the curve (AUC) values are equivalent between oral and IV routes
  • No dose adjustment is required when switching between formulations

Comparative Pharmacokinetic Parameters

Looking at the FDA data for 600 mg dosing 1:

  • Oral tablet: AUC 91.4 mcg•h/mL (single dose), 138.0 mcg•h/mL (steady-state)
  • IV injection: AUC 80.2 mcg•h/mL (single dose), 89.7 mcg•h/mL (steady-state)

The slight differences reflect normal pharmacokinetic variability rather than meaningful bioavailability differences. The clearance rates are also comparable (127 mL/min oral vs 138 mL/min IV for single doses) 1.

Clinical Implications

This equivalent bioavailability has important practical applications:

  • Seamless IV-to-oral conversion: Patients can be switched from IV to oral therapy without changing the dose (600 mg every 12 hours for adults) as soon as they can tolerate oral intake 3
  • Outpatient oral therapy: The oral formulation achieves the same therapeutic concentrations as IV, making it suitable for outpatient treatment of serious infections 4
  • Cost and convenience: Oral therapy eliminates IV access complications and reduces healthcare costs while maintaining equivalent efficacy

Food Effect Considerations

While food slightly delays absorption (Tmax increases from 1.5 to 2.2 hours) and reduces Cmax by approximately 17%, the total drug exposure (AUC) remains unchanged 1, 2, 5. Therefore, linezolid may be administered without regard to meals.

Supporting Research Evidence

Multiple studies confirm this bioequivalence:

  • A crossover study demonstrated mean absolute bioavailability of 103% (±20%) for oral tablets compared to IV administration 5
  • Research in hospitalized patients receiving enteral feedings showed linezolid oral suspension was "rapidly and completely absorbed" with bioavailability "unaltered" by enteral feedings 6
  • Pharmacokinetic studies consistently show "linear pharmacokinetics" with "concentrations remaining above target MIC90 for most of the dosing interval" regardless of route 7, 8

Bottom line: The 600 mg oral tablet and 600 mg IV formulation deliver equivalent systemic drug exposure, allowing interchangeable use based solely on patient factors (ability to take oral medications, clinical stability) rather than pharmacokinetic considerations.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.